Avalyn plots $182M IPO; WHO prequalifies Novartis' malaria drug

Avalyn Pharma plots $182M IPO: The biotech, which is making inhaled versions of approved pulmonary fibrosis medicines, anticipates about $182 million in net proceeds if it prices its initial public offering ...